Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

Executive Summary

The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.

Advertisement

Related Content

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
Lilly/Loxo Deal Came Together Quickly
FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer
Bayer Eyes More Link-Ups Like Loxo After Pipeline Blips
More Good News For Bayer's Larotrectinib Ahead Of FDA Verdict
Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market
New EU Speedy Review Hopefuls: Novimmune, AveXis, bluebird bio, and Loxo Oncology
Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice
Oncology: Tissue-Agnostic Indications Advance Under US FDA's Breakthrough Umbrella

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099881

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel